Understanding how a by-product of metabolism affects brain aging and Alzheimer's disease
Methylglyoxal drives astrocyte senescence to mediate neurodegeneration in Alzheimer's disease
This study is looking at how a natural substance in our bodies called methylglyoxal affects important brain cells as we age, especially in relation to Alzheimer's disease, and aims to find ways to help these cells stay healthy longer, which could lead to new treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Buck Institute for Research on Aging NIH-funded |
| Lab location | 1 site (Novato, United States) |
| Project ID | NIH-10893338 on NIH RePORTER |
What this research studies
This research investigates how methylglyoxal, a by-product of metabolism, contributes to the aging of astrocytes, which are crucial brain cells. The study aims to uncover the mechanisms behind astrocyte senescence and how it leads to neurodegeneration in Alzheimer's disease. By enhancing the detoxification of methylglyoxal, the researchers hope to mitigate the effects of aging on these cells and reduce the risk of Alzheimer's-related neurodegeneration. Patients may benefit from potential new therapeutic strategies that target these processes.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults at risk of or diagnosed with Alzheimer's disease.
Not a fit: Patients with early-stage Alzheimer's disease or those without any cognitive impairment may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down the progression of Alzheimer's disease and improve brain health in aging populations.
How similar studies have performed: Other research has shown promising results in targeting metabolic by-products to improve neurodegenerative conditions, suggesting that this approach may be viable.
Where this research is happening
Novato, United States
- Buck Institute for Research on Aging — Novato, United States (Active)
Researchers
- Principal investigator: Kapahi, Pankaj — Buck Institute for Research on Aging
- Study coordinator: Kapahi, Pankaj
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.